The immaculate carbapenemase study

Journal of Clinical Microbiology

Volumn 55, Issue 6, 2017, Pages 1608-1611

  Thomson, Kenneth S ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM; CARBAPENEMASE; DORIPENEM; ERTAPENEM; MEROPENEM; BACTERIAL PROTEIN; BETA LACTAMASE; IMIPENEM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GENE; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; HUMAN; INFECTION CONTROL; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; NOTE; PANDEMIC; PRIORITY JOURNAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION;

BACTERIAL PROTEINS; BETA-LACTAMASES; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; IMIPENEM;

EID: 85019573851     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00430-17     Document Type: Note

References (20)

1. Carmeli Y, Akova M, Cornaglia G, Daikos GL, Garau J, Harbarth S, Rossolini GM, Souli M, Giamarellou H. 2010. Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control. Clin Microbiol Infect 16:102-111. https://doi.org/10.1111/j.1469-0691.2009.03115.x.
2. Watanabe M, Iyobe S, Inoue M, Mitsuhashi S. 1991. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 35:147-151. https://doi.org/10.1128/AAC.35.1.147.
3. Walsh TR. 2010. Emerging carbapenemases: a global perspective. Int J Antimicrob Agents 36(Suppl 3):S8-S14. https://doi.org/10.1016/S0924-8579(10)70004-2.
4. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; 20th informational supplement M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
5. de Araujo CF, Silva DM, Carneiro MT, Ribeiro S, Fontana-Maurell M, Alvarez P, Asensi MD, Zahner V, Carvalho-Assef AP. 2016. Detection of carbapenemase genes in aquatic environments in Rio de Janeiro, Brazil. Antimicrob Agents Chemother 60:4380-4383. https://doi.org/10.1128/AAC.02753-15.
6. Walsh TR, Toleman MA. 2012. The emergence of pan-resistant Gram-negative pathogens merits a rapid global political response. J Antimicrob Chemother 67:1-3. https://doi.org/10.1093/jac/dkr378.
7. Livermore DM, Andrews JM, Hawkey PM, Ho PL, Keness Y, Doi Y, Paterson D, Woodford N. 2012. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? J Antimicrob Chemother 67:1569-1577. https://doi.org/10.1093/jac/dks088.
8. Thomson KS. 2010. Extended-spectrum-beta-lactamase, AmpC, and carbapenemase issues. J Clin Microbiol 48:1019-1025. https://doi.org/10.1128/JCM.00219-10.
9. Tzouvelekis LS, Markogiannakis A, Piperaki E, Souli M, Daikos GL. 2014. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 20:862-872. https://doi.org/10.1111/1469-0691.12697.
10. EUCAST. 2013. EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Resistance-mechanisms/EUCAST-detection-of-resistance-mechanisms-v1.0-20131211.pdf.
11. Clinical and Laboratory Standards Institute. 2016. Performance standards for antimicrobial susceptibility testing; 25th informational supplement M100-S26. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Bratu S, Landman D, Haag R, Recco R, Eramo A, Alam M, Quale J. 2005. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 165:1430-1435. https://doi.org/10.1001/archinte.165.12.1430.
13. Bratu S, Mooty M, Nichani S, Landman D, Gullans C, Pettinato B, Karumudi U, Tolaney P, Quale J. 2005. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob Agents Chemother 49:3018-3020. https://doi.org/10.1128/AAC.49.7.3018-3020.2005.
14. Bratu S, Landman D, Alam M, Tolentino E, Quale J. 2005. Detection of KPC carbapenem-hydrolyzing enzymes in Enterobacter spp. from Brooklyn, New York. Antimicrob Agents Chemother 49:776-778. https://doi.org/10.1128/AAC.49.2.776-778.2005.
15. Samra Z, Ofir O, Lishtzinsky Y, Madar-Shapiro L, Bishara J. 2007. Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel. Int J Antimicrob Agents 30:525-529. https://doi.org/10.1016/j.ijantimicag.2007.07.024.
16. Pournaras S, Kristo I, Vrioni G, Ikonomidis A, Poulou A, Petropoulou D, Tsakris A. 2010. Characteristics of meropenem heteroresistance in Klebsiella pneumoniae carbapenemase (KPC)-producing clinical isolates of K. pneumoniae. J Clin Microbiol 48:2601-2604. https://doi.org/10.1128/JCM.02134-09.
17. Thomson KS, Robledo IE, Vazquez GJ, Moland ES. 2011. KPC screening by updated BD Phoenix and Vitek 2 automated systems. J Clin Microbiol 49:3386-3387. https://doi.org/10.1128/JCM.00772-11.
18. Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME. 2005. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 41:149-158. https://doi.org/10.1086/430912.
19. Paul M, Lador A, Grozinsky-Glasberg S, Leibovici L. 7 January 2014. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev https://doi.org/10.1002/14651858.CD003344.pub3:CD003344.
20. Karlowsky JA, Lob SH, Kazmierczak KM, Badal RE, Young K, Motyl MR, Sahm DF. 2017. In vitro activity of imipenem against carbapenemase-positive Enterobacteriaceae isolates collected by the SMART Global Surveillance Program from 2008 to 2014. J Clin Microbiol 55:1638-1649. https://doi.org/10.1128/JCM.02316-16.